Please provide your email address to receive an email when new articles are posted on . BOSTON — New recommendations from ACP on type 2 diabetes treatment include adding a GLP-1 agonist or SGLT-2 ...
BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...
Results showed that use of GLP-1 receptor agonists did not increase short-term medical or surgical complications among ...
Among patients with type 2 diabetes, glucagon-like peptide 1 (GLP-1) receptor agonists reduced their risk of obesity-related cancers more than insulin did. Use of the drug class was also linked to a ...
GLP-1 receptor agonists hold key market opportunities due to their effectiveness in diabetes and obesity management, expanding to cardiovascular and neurodegenerative disorders. Innovations like oral ...
Diabetic patients treated with GLP-1 receptor agonists (GLP-1RAs) had a significantly lower risk of developing glaucoma as compared with metformin, a large retrospective cohort study showed. Patients ...
About The Study: Glucagon-like peptide receptor agonists (GLP-1RAs) were associated with lower risks of specific types of obesity-associated cancers compared with insulins or metformin in patients ...
Research suggests the drugs have potential for prevention and harm reduction in substance use disorders, writes Ziyad Al-Aly People taking glucagon-like peptide-1 (GLP-1) receptor agonists often ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results